TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
RENO, NV, UNITED STATES, April 9, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies ...
The renewal highlights ongoing progress in developing rhLAM-111 for rare muscular diseases, with a new emphasis on Duchenne Muscular Dystrophy. We are excited to have renewed our EU Orphan Drug ...
Genetic testing is available for adults as well as in vitro embryos, fetuses, newborns, and older children. Adults Adults planning to have children are advised to get genetic testing for muscular ...
This quick alphabetical guide will help you feel more confident when talking about muscular dystrophy with your doctor and loved ones. Muscular dystrophy is the name for a group of genetic diseases ...
(KXAN) — The U.S. Food and Drug Administration has authorized testing to aid in newborn screenings of Duchenne Muscular Dystrophy, a rare genetic disorder that causes progressive muscle deterioration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback